Research Paper
Year: 2022 | Month: March | Volume: 9 | Issue: 3 | Pages: 166-172
DOI: https://doi.org/10.52403/ijrr.20220320
A Comparative Study of Olopatadine Hydrochloride and Bepotastine Besilate in the Treatment of Allergic Conjunctivitis
Archana V. Manekar1, Sharayu Ashok Bhore2
1Professor, Department of Ophthalmology, DR PDMMC, Amravati
2Junior Resident, Department of Ophthalmology, DR PDMMC, Amravati.
Corresponding Author: Sharayu Ashok Bhore
ABSTRACT
Background -Ocular allergy is a commonly encountered pathology in clinical practice, which often is under diagnosed and consequently undertreated. These are rarely vision-threatening but can significantly decrease the quality of life for patients. Olopatadine and Bepotastine eyedrop have both antihistaminic and mast cell stabilization action. Their use can control acute symptoms and prevent relapses as well. We conducted this single blinded trial directly comparing the efficacy of the two topical anti allergic medications in mild forms of allergic conjunctivitis.
Materials and Methods - A single blinded randomised control clinical trial study was conducted in patients visiting OPD of Ophthalmology at the institute for duration of 6 months. All the patients above 18 years of age having mild to moderate allergic conjunctivitis were included in the study. Patients were randomly placed in one of the two groups according to computer generated random numbers and given topical anti-allergic medication for twice daily. Group A was given Topical 0.1% Olopatadine eye drops BD and Group B was given Topical 1.5% Bepotastine eye drops BD. Ophthalmological check-up was done using slit lamp on next day, after 1 week, after 21-28 days.
Results - It was seen from the study that on follow up day 1 in patients receiving Bepotastine 1.5% eyedrop, there was 50% relief of symptoms and signs seen in 80% patients while in 60% patients, only 40% relief in symptoms and sign was seen with olopatadine 0.1% eyedrop. On follow up day 7, 90% of symptoms and signs of allergic conjunctivitis were relieved in all patients receiving Bepotastine eyedrop while 80% relief was seen in those receiving olopatadine. Almost 100% relief from signs and symptoms were seen in both the groups on follow up day 21-28th.
Conclusion- We conclude from our study that, Bepotastine besilate 1.5% ophthalmic solution is a preferred drug compared to Olopatadine 0.1% in the immediate relief of symptoms and signs of allergic conjunctivitis. It can be used as an initial therapy in the symptom relief and alternative to the topical steroids used in mild-moderate allergic conjunctivitis.
Keywords: Allergic conjunctivitis, Ocular allergy, Olopatadine hydrochloride, Bepotastine besilate.
[PDF Full Text]